NASDAQ:MTAC MedTech Acquisition (MTAC) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free MTAC Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$8.96▼$12.8350-Day Range$9.34▼$11.3452-Week Range$8.43▼$12.83Volume183,276 shsAverage Volume9,656 shsMarket Capitalization$83.80 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get MedTech Acquisition alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About MedTech Acquisition Stock (NASDAQ:MTAC)MedTech Acquisition Corporation does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the healthcare sector in the United States. The company was incorporated in 2020 and is based in Greenwich, Connecticut. MedTech Acquisition Corporation operates as a subsidiary of Medtech Acquisition Sponsor LLC.Read More Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. MTAC Stock News HeadlinesJanuary 23, 2024 | msn.comJohnson & Johnson’s MedTech performance augurs well for industry: analystsJanuary 23, 2024 | msn.comJohnson & Johnson’s earnings beat estimates with boost from medtech salesApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.November 29, 2023 | forbes.com5 Tips To Ensure Product-Market Fit In MedtechNovember 15, 2023 | bizjournals.comWestminster oncology company holds first earnings call since going publicNovember 14, 2023 | finance.yahoo.comTriSalus Reports Third Quarter 2023 Financial Results and Provides Business UpdateSeptember 25, 2023 | forbes.comThe Art Of A Profitable Medtech ExitAugust 8, 2023 | markets.businessinsider.comPre-market Movers: MTAC, AYX, DDOG, IFF, CHGG…April 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.August 3, 2023 | finance.yahoo.comMedTech Acquisition Corporation Adjourns Special Meeting of StockholdersJuly 20, 2023 | msn.comJohnson & Johnson posts Q2 beat as Pharma, MedTech outperformMay 30, 2023 | msn.comMorgan Stanley's top medtech picks are Medtronic, Alphatec, Becton DickinsonMay 10, 2023 | investing.comLAVA Medtech Acquisition Corp (LVAC)April 26, 2023 | forbes.comSix Ways To Lead The Charge In MedtechApril 20, 2023 | finance.yahoo.comTriSalus Life Sciences Presents New Data at AACR for SD-101 Delivered by the Proprietary PEDD™ Method in Stage IV Uveal Melanoma Patients With Liver MetastasesFebruary 21, 2023 | finance.yahoo.comTriSalus Life Sciences Appoints James Alecxih to Lead Device Technology BusinessDecember 8, 2022 | yahoo.comMedTech Acquisition Corporation Announces Adjournment of its Special Meeting in lieu of an Annual Meeting of StockholdersNovember 16, 2022 | finance.yahoo.comTriSalus Goes SPAC Way To Fund Pressure-Enabled Drug Delivery Tech Based Cancer TrialsNovember 14, 2022 | finance.yahoo.comTriSalus Life Sciences to Become Publicly Traded Through Merger With MedTech Acquisition CorporationAugust 9, 2022 | finance.yahoo.comGlobal MedTech Healthcare IT Industry Competitive LandscapeJuly 27, 2022 | apnews.comLSI Emerging Medtech Summit 2022 Brings Venture Capital and Entrepreneurs Closer in New Event in EuropeJuly 15, 2022 | benzinga.comOphthalmic Devices Market is expected to be worth USD 83.1 billion by 2030, with a CAGR of 4.7%.June 12, 2022 | seekingalpha.comMedtronic: Stable Growth AheadMay 31, 2022 | msn.com3 Med-Tech Stocks With Incredible PotentialMay 27, 2022 | seekingalpha.comMedtronic plc (MDT) CEO Geoff Martha on Q4 2022 Results - Earnings Call TranscriptApril 8, 2022 | finance.yahoo.comMedTech Acquisition Corporation (MTAC)March 10, 2022 | seekingalpha.comSPAC MedTech Acquisition, Memic Innovative Surgery call off planned mergerSee More Headlines Receive MTAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MedTech Acquisition and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:MTAC CUSIPN/A CIK1826667 WebN/A Phone908-391-1288FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$5.54 million Net MarginsN/A Pretax MarginN/A Return on Equity-17.92% Return on Assets-1.48% Debt Debt-to-Equity RatioN/A Current Ratio0.03 Quick Ratio0.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.89 per share Price / Cash Flow12.80 Book Value($2.04) per share Price / Book-5.56Miscellaneous Outstanding Shares7,390,000Free Float1,952,000Market Cap$83.80 million OptionableNot Optionable Beta-0.04 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Christopher C. Dewey (Age 79)CEO & Director Mr. David J. Matlin J.D. (Age 61)CFO & Director Mr. Robert H. Weiss J.D. (Age 64)Chief Admin. Officer & Sec. Key CompetitorsPersonalisNASDAQ:PSNLEnzo BiochemNYSE:ENZBiodesixNASDAQ:BDSXAkuminNASDAQ:AKUMQExagenNASDAQ:XGNView All Competitors This page (NASDAQ:MTAC) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyProtect Your Bank Account Before It’s Too LateWeiss RatingsHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe World's First "$20 Trillion Drug?"Behind the MarketsBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MedTech Acquisition Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
